Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China
Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical...
Simcere Pharmaceutical
Simcere Pharmaceutical’s Cosela Receives NMPA Review for ES-SCLC Indication
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...
Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278
China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...
Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...
Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablets for AIS Accepted by NMPA for Review
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that the National Medical Products Administration...
Mass General Brigham Partners with Simcere Pharmaceutical for Cancer and Autoimmune Disease Research
Top-tier US medical institution Mass General Brigham Incorporated (MGB) has signed a sponsored research agreement...
Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials
Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...
Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications
Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical...
Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines
The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...
Neurodawn Completes Series A+ Financing for CNS Drug Development
Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has...
Beijing HSA Sets Price for Hainan Simcere’s COVID-19 Therapy SIM0417
Beijing’s municipal Healthcare Security Administration (HSA) bureau has released details of the initial quote and...
Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the issuance of the first prescription for...
Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...
Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...
Apeloa and Simcere Partner for CDMO Services and R&D Collaboration
China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...
Simcere Receives NMPA Clearance for SIM0348 Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...
Simcere Receives NMPA Clearance for SIM0237 Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...
Simcere Pharmaceutical Completes Enrollment for SIM0417 COVID-19 Drug Trial
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of enrollment of 1,208 patients...